IONS logo

IONS
Ionis Pharmaceuticals Inc

6,658
Mkt Cap
$13.41B
Volume
2.77M
52W High
$86.74
52W Low
$23.95
PE Ratio
-32.90
IONS Fundamentals
Price
$81.15
Prev Close
$80.60
Open
$80.59
50D MA
$81.26
Beta
0.70
Avg. Volume
2.4M
EPS (Annual)
-$2.38
P/B
21.16
Rev/Employee
$673,117.69
$12,595.28
Loading...
Loading...
News
all
press releases
Ionis Pharmaceuticals, Inc. $IONS Shares Bought by Envestnet Asset Management Inc.
Envestnet Asset Management Inc. grew its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 103.1% in the third quarter, according to its most recent disclosure with the...
MarketBeat·19h ago
News Placeholder
More News
News Placeholder
Ionis Pharmaceuticals CEO Teases Late-June Olezarsen Launch After FDA Priority Review Acceptance
Ionis Pharmaceuticals (NASDAQ:IONS) CEO Brett Monia told investors at Oppenheimer's 36th Annual Healthcare Life Sciences Conference that the company received FDA acceptance of its supplemental NDA...
MarketBeat·2d ago
News Placeholder
Ionis Pharmaceuticals (NASDAQ:IONS) Downgraded by Wall Street Zen to Sell
Wall Street Zen cut shares of Ionis Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat·2d ago
News Placeholder
Ionis Pharmaceuticals (NASDAQ:IONS) Given New $100.00 Price Target at Piper Sandler
Piper Sandler lifted their price objective on Ionis Pharmaceuticals from $87.00 to $100.00 and gave the stock an "overweight" rating in a research note on Friday...
MarketBeat·2d ago
News Placeholder
Ionis to present new data supporting DAWNZERA (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced new data to be presented for DAWNZERA (donidalorsen), the first and only RNA-targeted medicine for hereditary angioedema (HAE), including...
Business Wire·3d ago
News Placeholder
TD Asset Management Inc Sells 144,418 Shares of Ionis Pharmaceuticals, Inc. $IONS
TD Asset Management Inc lowered its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 13.1% during the third quarter, according to the company in its most recent filing with the...
MarketBeat·3d ago
News Placeholder
Dana Investment Advisors Inc. Acquires Shares of 18,818 Ionis Pharmaceuticals, Inc. $IONS
Dana Investment Advisors Inc. bought a new position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities...
MarketBeat·3d ago
News Placeholder
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $77.00
Stifel Nicolaus boosted their price objective on shares of Ionis Pharmaceuticals from $73.00 to $77.00 and gave the company a "hold" rating in a research note on Thursday...
MarketBeat·4d ago
News Placeholder
Ionis Q4 Earnings & Sales Beat, Stock Down on Soft 2026 Outlook
IONS beats Q4 estimates on strong Tryngolza sales, but shares slip 5% as 2026 revenue outlook and slower uptake for new drugs weigh on sentiment.
Zacks·4d ago
News Placeholder
Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for olezarsen...
Business Wire·4d ago
<
1
2
...
>

Latest IONS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.